Martin Shkreli of the Turing Pharmaceuticals pricing controversy now leads a group of investors taking former penny stock KaloBios on a steep roller-coaster ride
TIM SHUFELT, The Globe and Mail
Wed, 11/25/2015 - 5:42pm
Martin Shkreli of the Turing Pharmaceuticals pricing controversy now leads a group of investors taking former penny stock KaloBios on a steep roller-coaster ride